ReferenceID 1207
Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy
Pharmacol Res
TMEM16A plays critical roles in physiological process and may serve as drug targets for diverse diseases. Recently, TMEM16A has started to be regarded as potential primary lung adenocarcinoma targets. Here, we identified
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 1207
- Evidence Id
- 17797
- Core Evidence Id
- 17797
- Source Reference Id
- 2401
- Herb2 Reference Id
- HBREF003198
- Subject Paper Key
- HBIN016609_32097750
- Pubmed Id
- 32097750
- Doi
- 10.1016/j.phrs.2020.104721
- Paper Title
- Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy
- Paper Abstract
- TMEM16A plays critical roles in physiological process and may serve as drug targets for diverse diseases. Recently, TMEM16A has started to be regarded as potential primary lung adenocarcinoma targets. Here, we identified that arctigenin, a natural compound, is a novel TMEM16A inhibitor, and it can suppress lung adenocarcinoma growth through inhibiting TMEM16A both in vitro and in vivo. Our data also showed that the IC50 of actigenin to TMEM16A whole-cell current was 19.29 +- 4.69 muM, and the putative binding sites of arctigenin in TMEM16A were R515 and R535. Arctigenin concentration-dependently inhibited the proliferation and migration of LA795, however, the inhibition effect can be abolished by knockdown of the endogenous TMEM16A with shRNA. Further, we injected arctigenin on xenograft mouse model which exhibited significant antitumor activity with no adverse effect. At last, western blotting results showed the mechanism of arctigenin inhibiting lung adenocarcinoma was through inhibiting MAPK pathway. In summary, TMEM16A is a novel drug target for lung adenocarcinoma treatment. Arctigenin can be used as a lead compound for the development of lung adenocarcinoma therapy drugs.
- Journal
- Pharmacol Res
- Publish Year
- 2020
- Experiment Subject
- mouse
- Experiment Type
- Animal Experiment
- Phenotype Related
- Lung Adenocarcinoma
- Paper Title Cn
- Paper Title En
- Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy
- Bilingual Status
- semi_complete